Company news
Engene Therapeutics Inc. (NASDAQ:ENGN) news
Engene Therapeutics Inc. news releases on 6ix. Latest, Sep 8, 2026: enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Press releases & updates
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
September 8, 2026
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
June 15, 2026
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
enGene Announces Name Change to enGene Therapeutics Inc.
April 6, 2026
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 8, 2026
EnGene : Amendment to Annual Report (Form 10-K/A)
February 19, 2026
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 20, 2026
enGene Reports Full Year 2025 Financial Results and Provides Business Update
December 22, 2025
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
December 16, 2025
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
December 2, 2025
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
November 13, 2025
enGene Announces Proposed Public Offering of Common Shares
November 12, 2025
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
November 11, 2025
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
November 10, 2025
enGene to Participate in Upcoming Investor Conferences
November 6, 2025
enGene Named a BioSpace 2026 Best Places to Work Winner
November 4, 2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 1, 2025
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
September 30, 2025
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
September 11, 2025
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
September 3, 2025
EnGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 4, 2025
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
July 8, 2025
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
June 25, 2025
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
June 12, 2025
enGene Announces the Resignation of its Chief Medical Officer
June 4, 2025
enGene to Present at the Jefferies Global Healthcare Conference
May 29, 2025
enGene Names Amy Pott as Chief Global Commercialization Officer
May 28, 2025
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
April 1, 2025
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
March 10, 2025
enGene to Participate in the Leerink Partners Global Healthcare Conference
March 4, 2025
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
January 29, 2025
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
December 18, 2024
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 4, 2024
enGene Announces $60 Million Private Placement Financing
October 24, 2024
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 21, 2024
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
October 20, 2024
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
September 25, 2024
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
September 9, 2024
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 23, 2024
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
July 23, 2024
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
June 13, 2024
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 14, 2024
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
May 1, 2024
/C O R R E C T I O N -- enGene Inc./
April 8, 2024
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
March 10, 2024
enGene To Present at the Leerink Partners Global Biopharma Conference
March 4, 2024